{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:58:56Z","timestamp":1790801936748,"version":"4.1.0"},"reference-count":67,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2021,4,19]],"date-time":"2021-04-19T00:00:00Z","timestamp":1618790400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibodies"],"abstract":"<jats:p>The targeted delivery of drugs by means of linking them to antibodies (Abs) to form antibody\u2013drug conjugates (ADCs) has become an important approach in oncology and could potentially be used in other therapeutic areas. Targeted therapy is aimed at improving clinical efficacy while minimizing adverse reactions. The nonclinical safety assessment of ADCs presents several unique challenges involving the need to examine a complex molecule, each component of which can contribute to the effects observed, in appropriate animal models. Some considerations for the nonclinical safety evaluation of ADCs based on a literature review of ADCs in clinical development (currently or previously) are discussed.<\/jats:p>","DOI":"10.3390\/antib10020015","type":"journal-article","created":{"date-parts":[[2021,4,19]],"date-time":"2021-04-19T11:21:38Z","timestamp":1618831298000},"page":"15","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Considerations for the Nonclinical Safety Evaluation of Antibody\u2013Drug Conjugates"],"prefix":"10.3390","volume":"10","author":[{"suffix":"Jr.","given":"J. Edward","family":"Fisher","sequence":"first","affiliation":[{"name":"Center for Drug Evaluation and Research (CDER), US Food and Drug Administration (FDA), Silver Spring, MD 20993, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,4,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e00535","DOI":"10.1002\/prp2.535","article-title":"The pharmacology and therapeutic applications of monoclonal antibodies","volume":"7","author":"Castelli","year":"2019","journal-title":"Pharmacol. Res. Perspect."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1177\/2472555220912955","article-title":"Advances in Antibody\u2013Drug Conjugate Design: Current Clinical Landscape and Future Innovations","volume":"25","author":"Sassoon","year":"2020","journal-title":"Slas Discov. Adv. Sci. Drug Discov."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/978-1-4939-9929-3_2","article-title":"Pushing the Envelope: Advancement of ADCs Outside of Oncology","volume":"2078","author":"McPherson","year":"2020","journal-title":"Methods Mol. Biol."},{"key":"ref_4","unstructured":"Saber, H., and Leighton, J.K. (2021, February 28). Antibody-Drug Conjugates: Simple Idea Complicated Matter. DIA Global Forum, Available online: https:\/\/globalforum.diaglobal.org\/issue\/october-2020\/."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"6398","DOI":"10.1158\/1078-0432.CCR-11-0487","article-title":"Antibody fusion proteins: Anti-CD22 recombinant immunotoxin moxetumomab pasudotox","volume":"17","author":"Kreitman","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"S307","DOI":"10.1016\/j.bbmt.2019.12.407","article-title":"A Novel Targeted Approach to Achieve Immune System Reset: CD45-Targeted Antibody Drug Conjugates Enable Autologous HSCT and Ameliorate Disease in Preclinical Autoimmune Disease Models","volume":"26","author":"Gillard","year":"2020","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.yrtph.2013.08.017","article-title":"Considerations for the nonclinical safety evaluation of antibody drug conjugates for oncology","volume":"67","author":"Roberts","year":"2013","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"ref_8","unstructured":"ICH S6(R1) 2011 (2021, February 28). Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals. Available online: www.ich.org."},{"key":"ref_9","unstructured":"ICH S9 2009 (2021, February 28). Nonclinical Evaluation for Anticancer Pharmaceuticals. Available online: www.ich.org."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.yrtph.2015.01.014","article-title":"An FDA oncology analysis of antibody-drug conjugates","volume":"71","author":"Saber","year":"2015","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"104429","DOI":"10.1016\/j.yrtph.2019.104429","article-title":"An FDA oncology analysis of toxicities associated with PBD-containing antibody-drug conjugates","volume":"107","author":"Saber","year":"2019","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1038\/nbt.1480","article-title":"Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index","volume":"26","author":"Junutula","year":"2008","journal-title":"Nat. Biotechnol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"5628","DOI":"10.1002\/jcp.27419","article-title":"Antibody\u2013drug conjugates (ADCs) for cancer therapy: Strategies, challenges, and successes","volume":"234","author":"Lotfinia","year":"2019","journal-title":"J. Cell Physiol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3526","DOI":"10.1007\/s11095-015-1657-7","article-title":"Current ADC Linker Chemistry","volume":"32","author":"Jain","year":"2015","journal-title":"Pharm. Res."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Mou, S., Huang, Y., and Rosenbaum, A.I. (2018). ADME Considerations and Bioanalytical Strategies for Pharmacokinetic Assessments of Antibody-Drug Conjugates. Antibodies, 7.","DOI":"10.3390\/antib7040041"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Lucas, A.T., Price, L.S.L., Schorzman, A.N., Storrie, M., Piscitelli, J.A., Razo, J., and Zamboni, W.C. (2018). Factors Affecting the Pharmacology of Antibody-Drug Conjugates. Antibodies, 7.","DOI":"10.3390\/antib7010010"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1177\/0192623310382559","article-title":"Use of Tissue Cross-reactivity Studies in the Development of Antibody-based Biopharmaceuticals: History, Experience, Methodology, and Future Directions","volume":"38","author":"Leach","year":"2010","journal-title":"Toxicol. Pathol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1093\/annonc\/mdw424","article-title":"Antibody drug conjugates: Lessons from 20 years of clinical experience","volume":"27","author":"Tolcher","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1200\/JCO.2000.18.11.2282","article-title":"Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-doxorubicin in patients with lewis Y-expressing epithelial tumors","volume":"18","author":"Saleh","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"ref_20","first-page":"3","article-title":"Development and activities of the BR96-doxorubicin immunoconjugate","volume":"166","author":"Senter","year":"2001","journal-title":"Methods Mol. Biol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1200\/JCO.1999.17.2.478","article-title":"Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer","volume":"17","author":"Tolcher","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Noble, P., Spendlove, I., Harding, S., Parsons, T., and Durrant, L.G. (2013). Therapeutic targeting of Lewis(y) and Lewis(b) with a novel monoclonal antibody 692\/29. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0054892"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1111\/bph.14784","article-title":"Evaluation and use of an anti-cynomolgus monkey CD79b surrogate antibody-drug conjugate to enable clinical development of polatuzumab vedotin","volume":"176","author":"Li","year":"2019","journal-title":"Br. J. Pharmacol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.yrtph.2014.04.005","article-title":"New challenges and opportunities in nonclinical safety testing of biologics","volume":"69","author":"Baumann","year":"2014","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1200\/JCO.19.02085","article-title":"First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody-Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors","volume":"38","author":"Hassan","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1080\/19420862.2016.1156829","article-title":"Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates","volume":"8","author":"Donaghy","year":"2016","journal-title":"MAbs"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.exer.2010.08.002","article-title":"Mesothelial proteins are expressed in the human cornea","volume":"91","author":"Jirsova","year":"2010","journal-title":"Exp. Eye Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"5139","DOI":"10.1158\/1078-0432.CCR-14-3383","article-title":"Preclinical Development of an Anti-NaPi2b (SLC34A2) Antibody-Drug Conjugate as a Therapeutic for Non-Small Cell Lung and Ovarian Cancers","volume":"21","author":"Lin","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1517\/14712598.2012.642357","article-title":"The use of an antibody drug conjugate, glembatumumab vedotin (CDX-011), for the treatment of breast cancer","volume":"12","author":"Keir","year":"2012","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"8810","DOI":"10.1096\/fj.202000651","article-title":"Glycoprotein nonmetastatic melanoma protein B: A key mediator and an emerging therapeutic target in autoimmune diseases","volume":"34","author":"Tsou","year":"2020","journal-title":"FASEB J."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.steroids.2017.10.013","article-title":"Glycoprotein Non-Metastatic Melanoma Protein B (GPNMB) and Cancer: A Novel Potential Therapeutic Target","volume":"133","author":"Taya","year":"2018","journal-title":"Steroids"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1158\/1078-0432.CCR-05-2018","article-title":"CR011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma","volume":"12","author":"Tse","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1002\/pbc.25099","article-title":"Initial testing (stage 1) of glembatumumab vedotin (CDX-011) by the pediatric preclinical testing program","volume":"61","author":"Kolb","year":"2014","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1002\/cncr.31892","article-title":"A phase 2 study of glembatumumab vedotin, an antibody-drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma","volume":"125","author":"Ott","year":"2019","journal-title":"Cancer"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"6064","DOI":"10.1158\/1078-0432.CCR-06-0910","article-title":"A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus","volume":"12","author":"Tijink","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_36","unstructured":"(2021, February 28). FDA: Multi-Discipline Review. Drugs@FDA: FDA-Approved Drugs, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2019\/761137Orig1s000MultiDiscliplineR.pdf."},{"key":"ref_37","unstructured":"(2021, February 28). FDA: US Prescribing Information: Enfortumab Vedotin-Ejfv, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/761137s000lbl.pdf."},{"key":"ref_38","unstructured":"(2021, February 28). FDA: US Prescribing Information: Belantamab Mafodotin-Blmf, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/761158s000lbl.pdf."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1038\/s41587-020-00757-8","article-title":"Specter of eye toxicity looms over BCMA-targeted therapy","volume":"38","author":"Dolgin","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.pharmthera.2019.04.008","article-title":"Potential mechanisms of target-independent uptake and toxicity of antibody-drug conjugates","volume":"200","author":"Mahalingaiah","year":"2019","journal-title":"Pharmacol. Ther."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1158\/0008-5472.CAN-17-3202","article-title":"Modulation of Macropinocytosis-Mediated Internalization Decreases Ocular Toxicity of Antibody-Drug Conjugates","volume":"78","author":"Zhao","year":"2018","journal-title":"Cancer Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1158\/1078-0432.CCR-20-2275","article-title":"FDA Approval Summary: Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Carcinoma","volume":"27","author":"Chang","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s10549-019-05179-y","article-title":"Corneal features in trastuzumab emtansine treatment: Not a rare occurrence","volume":"175","author":"Deklerck","year":"2019","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/00003226-200101000-00016","article-title":"Expression of the receptor tyrosine kinases, epidermal growth factor receptor, ErbB2, and ErbB3, in human ocular surface epithelia","volume":"20","author":"Liu","year":"2001","journal-title":"Cornea"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1089\/jop.2015.0064","article-title":"Ocular Adverse Events Associated with Antibody-Drug Conjugates in Human Clinical Trials","volume":"31","author":"Eaton","year":"2015","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.taap.2013.09.003","article-title":"Preclinical safety profile of trastuzumab emtansine (T-DM1): Mechanism of action of its cytotoxic component retained with improved tolerability","volume":"273","author":"Poon","year":"2013","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"ref_47","unstructured":"(2021, February 28). FDA: US Prescribing Information: Ado-Trastuzumab Emtansine, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/125427s105lbl.pdf."},{"key":"ref_48","first-page":"13","article-title":"Trastuzumab-mediated cardiotoxicity: Current understanding, challenges, and frontiers","volume":"1","author":"Mohan","year":"2018","journal-title":"Antib. Ther."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ejca.2019.11.023","article-title":"Trastuzumab emtansine (T-DM1)-associated cardiotoxicity: Pooled analysis in advanced HER2-positive breast cancer","volume":"126","author":"Ameye","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"6417","DOI":"10.1158\/1078-0432.CCR-11-0486","article-title":"Antibody-drug conjugates of calicheamicin derivative: Gemtuzumab ozogamicin and inotuzumab ozogamicin","volume":"17","author":"Ricart","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_51","first-page":"1490","article-title":"Approval summary: Gemtuzumab ozogamicin in relapsed acute myeloid leukemia","volume":"7","author":"Bross","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1158\/1078-0432.CCR-16-0939","article-title":"Liver Microvascular Injury and Thrombocytopenia of Antibody-Calicheamicin Conjugates in Cynomolgus Monkeys-Mechanism and Monitoring","volume":"23","author":"Guffroy","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1182\/blood-2017-01-762419","article-title":"Sinusoidal obstruction syndrome following CD33-targeted therapy in acute myeloid leukemia","volume":"129","author":"Godwin","year":"2017","journal-title":"Blood"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s002800050995","article-title":"Toxicity of dolastatin 10 in mice, rats and dogs and its clinical relevance","volume":"44","author":"Mirsalis","year":"1999","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1177\/0192623318803059","article-title":"A Brief Introduction to Antibody-Drug Conjugates for Toxicologic Pathologists","volume":"46","author":"Mecklenburg","year":"2018","journal-title":"Toxicol. Pathol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"5552","DOI":"10.1158\/1078-0432.CCR-15-0468","article-title":"Preclinical Efficacy and Safety Assessment of an Antibody-Drug Conjugate Targeting the c-RET Proto-Oncogene for Breast Carcinoma","volume":"21","author":"Nguyen","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s10637-012-9801-2","article-title":"Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors","volume":"31","author":"Annunziata","year":"2013","journal-title":"Investig. New Drugs"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1021\/bc9002019","article-title":"Antibody-drug conjugates: Linking cytotoxic payloads to monoclonal antibodies","volume":"21","author":"Ducry","year":"2010","journal-title":"Bioconjug. Chem."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Lu, J., Jiang, F., Lu, A., and Zhang, G. (2016). Linkers Having a Crucial Role in Antibody-Drug Conjugates. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17040561"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1208\/s12248-014-9710-8","article-title":"Antibody drug conjugates: Design and selection of linker, payload and conjugation chemistry","volume":"17","author":"McCombs","year":"2015","journal-title":"AAPS J."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/nbt832","article-title":"Development of potent monoclonal antibody auristatin conjugates for cancer therapy","volume":"21","author":"Doronina","year":"2003","journal-title":"Nat. Biotechnol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1158\/1535-7163.MCT-15-1004","article-title":"Molecular Basis of Valine-Citrulline-PABC Linker Instability in Site-Specific ADCs and Its Mitigation by Linker Design","volume":"15","author":"Dorywalska","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1715705","DOI":"10.1080\/19420862.2020.1715705","article-title":"Improved translation of stability for conjugated antibodies using an in vitro whole blood assay","volume":"12","author":"Chu","year":"2020","journal-title":"MAbs"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1016\/j.xphs.2020.01.029","article-title":"Effect of Linker-Drug Properties and Conjugation Site on the Physical Stability of ADCs","volume":"109","author":"Mills","year":"2020","journal-title":"J. Pharm. Sci."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1021\/acs.molpharmaceut.8b00177","article-title":"Impact of Payload Hydrophobicity on the Stability of Antibody-Drug Conjugates","volume":"15","author":"Buecheler","year":"2018","journal-title":"Mol. Pharm."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1021\/bc9001097","article-title":"Design, synthesis, and biological evaluation of antibody-drug conjugates comprised of potent camptothecin analogues","volume":"20","author":"Burke","year":"2009","journal-title":"Bioconjug. Chem."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.yrtph.2016.10.012","article-title":"Peripheral neuropathy with microtubule inhibitor containing antibody drug conjugates: Challenges and perspectives in translatability from nonclinical toxicology studies to the clinic","volume":"82","author":"Stagg","year":"2016","journal-title":"Regul. Toxicol. Pharmacol."}],"container-title":["Antibodies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4468\/10\/2\/15\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:49:38Z","timestamp":1760161778000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4468\/10\/2\/15"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,19]]},"references-count":67,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,6]]}},"alternative-id":["antib10020015"],"URL":"https:\/\/doi.org\/10.3390\/antib10020015","relation":{},"ISSN":["2073-4468"],"issn-type":[{"value":"2073-4468","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,19]]}}}